• In the past week, Globus Medical, Inc. reported second-quarter 2026 results showing sales of US$789.61 million, up from US$745.34 million a year earlier, while net income declined to US$151.57 million from US$202.85 million and diluted EPS fell to US$1.10 from US$1.49.
• Over the first half of 2026, the company grew sales to US$1.55 billion from US$1.34 billion with largely flat net income, and reaffirmed its full-year revenue outlook of US$3.18 billion to US$3.22 billion, highlighting solid top-line progress amid pressure on profitability.
• Next, we’ll explore how reaffirmed full-year revenue guidance despite softer quarterly profitability affects Globus Medical’s existing investment narrative and expectations.

AI is about to change healthcare. These 42 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Globus Medical Investment Narrative Recap

To own Globus Medical, you need to believe the company can translate its growing spine and orthopedic revenue into durable profits as it scales robotics and recent acquisitions. The latest quarter supports the revenue story but highlights margin pressure, which keeps integration and cost control as the key short term catalyst, while acquisition and international execution risks remain central. Reaffirmed full year revenue guidance suggests this quarter’s profit softness does not yet materially alter that near term setup.

In that context, the reaffirmed 2026 revenue outlook of US$3.18 billion to US$3.22 billion is especially relevant. It anchors expectations that, despite a weaker Q2 net income and EPS, management still sees the top line tracking to plan. For investors focused on margin expansion from NuVasive and Nevro synergies and higher mix from enabling technologies, this guidance keeps attention on whether future quarters can show improving profitability alongside that revenue.

But while revenue guidance held firm, investors should be aware that margin pressure and acquisition integration risks could still...

Globus Medical's narrative projects $3.7 billion revenue and $767.1 million earnings by 2029.

Uncover how Globus Medical's forecasts yield a $103.23 fair value, a 20% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts once expected revenue around US$3.8 billion and earnings near US$684 million by 2029, which is far more upbeat than consensus and could look different after a quarter where revenue grew but profit slipped, so it is worth comparing how those views stack up against the recent margin pressure and the risk that cost-focused integration may not deliver as cleanly as hoped.

Explore 5 other fair value estimates on Globus Medical - why the stock might be worth over 2x more than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Globus Medical research is our analysis highlighting 5 key rewards that could impact your investment decision.
• Our free Globus Medical research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Globus Medical's overall financial health at a glance.

Seeking Other Investments?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• Uncover the next big thing with 20 elite penny stocks that balance risk and reward.
• Invest in the nuclear renaissance through our list of 92 elite nuclear energy infrastructure plays powering the global AI revolution.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 17 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.